CHOICELY
The Eurovision Song Contest (ESC), the world’s largest live music event, has renewed their mobile app in time for this year’s event in Malmö, Sweden. The app was built using Choicely’s no code app platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501446902/en/
Eurovision Song Contest built their new mobile app with a no code platform. The app was built using Choicely’s no code app platform. The Eurovision app boasts an extensive news feed and media portal, and engagement tools full of interactive fan activations like the Scoreboard. With it, viewers can establish their own classic Eurovision ranking from 12 points on, and share the ranking on social media. (Graphic: Business Wire)
“We were looking for a specialized partner who enables us to develop our app with speed and flexibility, so we can better serve the Eurovision fans across the globe,“ says Dave Goodman, ESC Digital and Communications Manager for Contest organizers, the European Broadcasting Union.
“We definitely got all of that in Choicely, and more,” Goodman emphasizes.
With Choicely, the app can be built without coding, using a visual drag and drop interface instead – like Wix or Wordpress for mobile apps.
“Despite Choicely being a no code platform, we got a fully tailormade app that matches our needs and our brand. Making improvements is quick and easy. We can focus on engaging our fans!” adds Dave Goodman from the EBU.
The Eurovision app boasts an extensive news feed and media portal, and engagement tools full of interactive fan activations like the Scoreboard. With it, viewers can establish their own classic Eurovision ranking from 12 points on, and share the ranking on social media.
During the Semi-Finals and Grand Final, viewers around the world can also easily vote through the app.
“We are proud to co-operate with the Eurovision Song Contest!” says Kaius Meskanen, CEO of Choicely. “It’s a legendary contest with a passionate global fanbase, and it reflects in everything they do,” Meskanen says.
“Together we have created a pixel-perfect app to serve the Eurovision fans, during the shows and in between them. It’s great to see the ESC organization enjoying the benefits of no code, like lower development costs, agile updates, and a better overall experience for the fans,” Meskanen points out.
Choicely was founded in Finland and it’s used by leaders in media, sports and entertainment companies, and across a range of industries in over 50 countries.
The renewed Eurovision Song Contest app can be found in Apple App Store and Google Play Store.
The Eurovision Song Contest is the world’s largest live music event. It is organized annually by the European Broadcasting Union (EBU), the world’s foremost alliance of public service media (PSM).
The competition, in which participating public service broadcasters that are Members of the EBU, send a new song to represent their nation, has taken place every year since 1956 except in 2020.
27 broadcasters have won the competition at least once.
37 broadcasters will take part in the 2024 Eurovision Song Contest in Malmö, Sweden hosted by SVT.
The 2023 competition reached over 170 million viewers around the world on TV and online.
The EBU represents 112 media organisations in 56 countries in Europe, the Middle East, and Africa; and have an additional 31 Associates in Asia, Africa, Australia, and the Americas. The EBU strives to secure a sustainable future for public service media.
Choicely’s no code app builder offers a simple, fast and affordable way to build and maintain high quality mobile apps. Choicely is based in Finland and Switzerland and currently serves businesses in over 50 countries. Choicely’s customers include the Eurovision Song Contest, Miss Universe, ITV Studios / Love Island TV Shows, and Iceland's national broadcasting organization RÚV.
Learn more about Choicely on their website.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501446902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom